Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation
TOKYO, Nov. 20, 2017 /CNW/ -- Daiichi Sankyo Co., Ltd. (JP: 4568.T,OTC: DSNKY) based in Tokyo, Japan and focused on pharmaceutical business, today announced that their November 15 presentation from Senior Director, IR group, Mr. Junichi Onuma, is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.
Daiichi Sankyo's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.
Recent Company Highlights
- 2017.10.31 Daiichi Sankyo Announces Determination of Matters Relating to Acquisition of Own Shares
- 2017.09.15 Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index
- 2017.09.12 Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
- 2017.08.30 Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.
SOURCE Daiichi Sankyo Co., Ltd.
For further information: Daiichi Sankyo Co., Ltd., Shinichi Kuga, Associate Director, IR Group, email@example.com, +81-3-6225-1156, http://www.daiichisankyo.com